Bristol-myers Squibb Compnay

Poxel Sa

Paul Strumph

Sébastien Bolze

Julie Dubourg

Ruby Holder

Margaret Smith Fletcher

Christophe Arbet-Engels

Karen Segal

Brandon Dale Swift

Bill Symonds

Sophie Bozec

Steve Piscitelli

Pascale Fouqueray

James F List

Mario Maldonado

Stephanie Moran

The present disclosure is directed to a method of treating prediabetes or type 1 or type 2 diabetes mellitus comprising administering to a subject in need thereof an effective amount of imeglimin, wherein the subject has chronic kidney disease.

Methods of treating subjects having diabetes with chronic kidney disease

The invention provides methods for treating a patient having type 2 diabetes who has failed on previous regimens of one or more oral and/or injectable anti-diabetic agents, which include the step of administering a therapeutically effective amount of an SGLT2 inhibitor alone or in combination with another anti-diabetic agent and/or other therapeutic agent to such patient. A pharmaceutical composition containing dapagliflozin or dapagliflozin-S-propylene glycol solvate and one or more diabetic agents and/or other therapeutic agents for use in the methods of the invention is also provided.

Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof

Methods are provided for treating cancers that have high glucose requirements and that express SGLT2 at levels higher than normal cells, such as metastatic cancers, for example, metastatic lung cancers, employing an SGLT2 inhibitor alone or in combination with a cytotoxic agent and to a composition containing a combination of an SGLT2 inhibitor and a cytotoxic agent.

Method for treating cancers having high glucose requirements employing an SGLT2 inhibitor and compositions thereof

Growing community of inventors

Moneta, VA, United States of America

Paul Strumph